FDA Awards Fast-Track Voucher for Kids' Rare Disease Drug
Published Date: 8/28/2025
Notice
Summary
The FDA just gave a special fast-track ticket called a priority review voucher to Chimerix, Inc. for their rare pediatric disease drug, MODESYO (dordaviprone), approved on August 6, 2025. This voucher helps speed up future drug reviews, benefiting companies working on rare kids' diseases and potentially getting treatments to patients faster. It’s a big win for rare disease drug developers and could impact how quickly new medicines reach the market.
Free Policy Watch
New rules are filed every week. Most people never see them.
Pick a topic. PRIA watches every federal rule and tells you when one hits your household.
Pick a topic to get started
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
Faster Reviews Could Reach Patients Sooner
The FDA says the priority review voucher helps speed up future drug reviews and could help get treatments for rare pediatric diseases to patients faster. The voucher was awarded for MODESYO (dordaviprone), approved August 6, 2025.
Priority Review Voucher Awarded to Company
The FDA issued a priority review voucher to Chimerix, Inc. for their rare pediatric disease product MODESYO (dordaviprone), which was approved on August 6, 2025. The voucher is an FDA-authorized tool that helps the sponsor speed up a future drug review.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in